-
Featured Authors
-
Archives
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Health
Latest From Health
Convention Attendees Make the Call on Expanded Access
The BIO International Convention kicked off Monday with an interactive session organized by the BIO Board Standing Committee on Bioethics: The Bioethics of Drug Development—You Make the Call. Attendees engaged in a real-time polling exercise addressing the many difficult issues related to expanded access using a mock case study of a company – iCures – dealing with an expanded access request. Moderator Steve Usdin, Senior Editor, BioCentury, led the panel through challenging issues in drug Read More >
Seek and Destroy
Ubiquibodies combine the specificity of antibodies with the destruction signal of ubiquitinization. Stand by for targeted destruction of disease-causing proteins in the cell Proteins in a cell that are aged or otherwise damaged are recycled via the ubiquitin-proteasome pathway (UPP). The doomed protein is first tagged with a protein called ubiquitin, which acts like a molecular sign reading “destroy me”, and then broken down by the proteasome, which is the cell’s recycling center. This catabolism Read More >
The Journey from the Bench to Bedside
A partnership between a leading academic research center and a biologics company is aiming to develop new therapeutic opportunities Translational research enables therapies get to where they need to be – to the patient. The process is characterized by collaborative activity between university and company scientists. One recent example is the announcement of a three-year collaboration between MedImmune, the global biologics research and development arm of AstraZeneca, and the Clinical and Translational Science Institute (CTSI) Read More >
Expand Investment in Basic Research Needed to Advance Medical Progress
In 2007, the Napier and Lane families struggled to find answers to their daughters’ developmental problems, which included impaired communication and socialization skills. Both of the girls had a disorder so rare that it subsequently became identified only by the name of the small fragment of chromosome 16 that was missing, namely “16p11.2 deletion syndrome.” Dan Pinkel and Joe Gray, researchers at the University of California, San Francisco developed microarray comparative genomic hybridization, a technology Read More >
Delivering the Right Dose, Less Often
Biologics are a growing area of drug development, including life-threatening and life-changing disorders such as cancer and rheumatoid arthritis. However, many biologics have short half-lives, and need to be dosed daily. To make them more convenient to use, as well as safer and more effective, researchers are developing delivery systems that keep the biologics in the body for longer, reducing the frequency of dosing. Swedish company Affibody is using the natural affinity of a naturally-occurring Read More >
